ASSESSMENT OF PAIN USING A PAIN DIAGNOSTIC SYSTEM THAT MEASURS FACIAL MOVEMENT USING
Launched by FATMAGÜL ÜSTÜNEL · Jun 26, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to assess pain in patients who are awake but unable to communicate verbally, such as those in intensive care after surgery. Researchers are using a special system that measures facial movements to better understand how much pain these patients are experiencing. This is important because healthcare providers may not always recognize pain in patients who can’t express it, leading to under-treatment.
To participate in the trial, you need to be at least 18 years old, currently conscious but unable to speak, and have a Glasgow Coma Scale score between 13 and 15, which indicates that you are alert and responsive. However, people with certain conditions, such as facial abnormalities or neurological disorders, cannot take part. If you join the study, you can expect to have your facial expressions analyzed to help healthcare providers assess your pain more accurately. This research aims to improve pain management for patients who face communication challenges during their recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years and over,
- • Those with intubation/tracheostomy,
- • Conscious, unable to communicate verbally,
- • Glaskow coma score 13-15,
- • Patients who agreed to participate in the study
- Exclusion Criteria:
- • Those with any facial abnormality that may alter facial expression analysis (facial paralysis, Poland-mobius syndrome)
- • Those with neurological and mental disorders,
- • Having a history of chronic pain,
- • Those who have a condition that requires them to be in the prone position all the time (Pilonidal Sinus, ARDS, etc.),
- • Patients who cannot speak the same language as the healthcare professional
About Fatmagül üstünel
Fatmagül Üstünel is a dedicated clinical trial sponsor with a focus on advancing medical research and improving patient outcomes. With a commitment to ethical practices and rigorous scientific methodology, the organization collaborates with healthcare professionals and institutions to conduct innovative studies across various therapeutic areas. Fatmagül Üstünel emphasizes transparency, safety, and compliance, ensuring that all trials adhere to regulatory standards while fostering an environment of trust and collaboration among stakeholders. Their mission is to contribute significantly to the development of new therapies and enhance the understanding of existing treatments through comprehensive clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adana, , Turkey
Patients applied
Trial Officials
Cukurova University Cukurova University
Study Director
Cukurova University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported